Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olaparib companion diagnostic - Myriad Genetics

Next Previous
X
Search
Drug Profile

Olaparib companion diagnostic - Myriad Genetics

Alternative Names: BRACAnalysis (Olaparib); BRACAnalysis (olaparib); BRACAnalysis CDx (Olaparib); Lynparza companion diagnostic; Olaparib - BRACAnalysis; Olaparib - BRACAnalysis CDx

Latest Information Update: 01 Dec 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Myriad Genetics
  • Developer AstraZeneca; Merck & Co; Myriad Genetics
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Breast cancer; Ovarian cancer
  • Registered Pancreatic cancer; Prostate cancer
  • No development reported Fallopian tube cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 01 Dec 2022 Olaparib companion diagnostic is still in phase III trial for Prostate Cancer in Canada, Denmark, France, Germany, Israel, Italy, Japan, South Korea, Netherlands, Norway, Spain, Sweden, Taiwan, Turkey, United Kingdom, Australia, Austria, Argentina, Brazil, (NCT02987543)
  • 09 Sep 2022 Efficacy and adverse event data from the Phase III SOLO-1 trial in Ovarian cancer presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)
  • 30 Aug 2022 Japan's MHLW approves olaparib companion diagnostic to identify patients with germline BRCA-mutated (gRBCAm) and HER2 negative, high-risk recurrent Breast cancer eligible for olaparib treatment

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top